Central Nervous System News and Research

RSS

GFAP levels predict brain injury, death in critically ill children on ECMO

Johns Hopkins Children's Center scientists have discovered that high blood levels of a protein commonly found in the central nervous system can predict brain injury and death in critically ill children on a form of life support called extra-corporeal membrane oxygenation or ECMO.

23 Nov 2010

Compugen announces development of Protein Family Members Discovery Platform

Compugen Ltd. announced today the development of its Protein Family Members Discovery Platform, designed for the discovery of novel protein members belonging to various known and clinically important protein families.

23 Nov 2010

Preclinical trial shows Chimerix’s CMX001 inhibits HSV replication

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that data demonstrating preclinical efficacy of Chimerix's lead antiviral compound CMX001 against herpes simplex virus (HSV) as well as its ability to penetrate the blood-brain barrier was published in the November 15, 2010 issue of The Journal of Infectious Diseases.

23 Nov 2010

USPTO issues patent for neurotherapeutic pharmaceutical formulation

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the U.S. Patent & Trademark Office has issued U.S. Patent 7,833,998 entitled, Oral Neurotherapeutic Cephalosporin Sulfoxide and Sulfone-containing Compositions.

23 Nov 2010

Myrexis announces poster presentation on Azixa at Neuro-Oncology Scientific Meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced a poster presentation of its lead product candidate Azixa (verubulin, MPC-6827) at the 2010 Society for Neuro-Oncology Scientific Meeting and Education Day in Montreal, Canada.

20 Nov 2010

CNS-ASU book explores relationship between nanotechnology and equity

Scientists and policymakers both contend that investments in nanoscale science and engineering will create revolutions in areas as diverse as materials, drug delivery, cancer treatment, and space travel. The hope is that many of the problems of today can be addressed using nanotechnology enabled products.

19 Nov 2010

New findings show promising treatment for MS

Successfully treating and reversing the effects of multiple sclerosis, or MS, may one day be possible using a drug originally developed to treat chronic pain, according to Distinguished Professor Linda Watkins of the University of Colorado at Boulder.

19 Nov 2010

Spleen cells may do more harm than good at site of spinal cord injury

The spleen, an organ that helps the body fight infections, might also be a source of the cells that end up doing more harm than good at the site of a spinal cord injury, new research suggests.

18 Nov 2010

Researchers discover NG2+ cells may impact ALS disease progression

By tracking the fate of a group of immature cells that persist in the adult brain and spinal cord, Johns Hopkins researchers discovered in mice that these cells undergo dramatic changes in ALS, also known as Lou Gehrig's disease.

18 Nov 2010

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Sangamo BioSciences, Inc. announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS.

17 Nov 2010

AACN endorses intraosseous vascular access

Recognizing that IV use is not always optimal to provide patients with fluids and medications, the American Association of Critical-Care Nurses (AACN) recently endorsed a consensus paper that recommends intraosseous (IO) vascular access in a variety of healthcare settings.

17 Nov 2010

Health professionals invited for 1st Asia-Pacific Osteoporosis Meeting

Healthcare providers in the Asia-Pacific region are coping with a rising tide of osteoporotic fractures. The IOF Regionals - 1st Asia- Pacific Osteoporosis Meeting, to take place in Singapore from December 10-13, 2010, is an ideal opportunity for health professionals in the region to acquire the latest practical information on osteoporosis and related fractures.

17 Nov 2010

Cardiac surgery leads to stroke, seizure and neurological complications: Report

Strokes, seizures and other neurological complications related to heart surgery account for "considerable morbidity and mortality," Loyola University Health System neurologists report in the November issue of the journal Hospital Practice.

17 Nov 2010

Research on CBS protein may lead to new drug design for homocystinuria disorder

University of Michigan researchers have solved the structure of a protein that is integral to processes responsible for maintaining a healthy heart and nervous system.

17 Nov 2010

U-M researcher awarded $600,000 grant for study of progesterone in treatment of children with TBI

A University of Michigan researcher has received a two-year, $600,000 grant to plan a randomized controlled study of progesterone for the treatment of traumatic brain injury in children.

17 Nov 2010

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes, Inc. today announced the presentation of promising preclinical results for its proprietary opioid modulator, ALKS 33, showing the drug candidate's potential in multiple disease indications.

17 Nov 2010

Neurologic complications remain an important cause of morbidity and mortality after heart surgeries

16 Nov 2010

Bayer presents results from Phase III ROCKET AF trial for atrial fibrillation at American Heart Association

Bayer today announced the results from the pivotal, double-blind Phase III, ROCKET AF trial. In the study, rivaroxaban demonstrated superiority to warfarin in reducing the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation (AF).

16 Nov 2010

Research suggests targeting spleen may promote healing of spinal cord injury

The spleen, an organ that helps the body fight infections, might also be a source of the cells that end up doing more harm than good at the site of a spinal cord injury, new research suggests.

16 Nov 2010

StemCells seeks Swiss authorization to conduct human neural stem cells clinical trial in chronic spinal cord injury

StemCells, Inc. announced today that is has filed an application with Swissmedic, the Swiss regulatory agency for therapeutic products, to conduct a clinical trial in Switzerland of the Company's HuCNS-SC® purified human neural stem cells in chronic spinal cord injury patients. If authorized, the study would enroll patients who are three to 12 months post-injury.

15 Nov 2010

Central Nervous System News and Research

GFAP levels predict brain injury, death in critically ill children on ECMO

Compugen announces development of Protein Family Members Discovery Platform

Preclinical trial shows Chimerix’s CMX001 inhibits HSV replication

USPTO issues patent for neurotherapeutic pharmaceutical formulation

Myrexis announces poster presentation on Azixa at Neuro-Oncology Scientific Meeting

CNS-ASU book explores relationship between nanotechnology and equity

New findings show promising treatment for MS

Spleen cells may do more harm than good at site of spinal cord injury

Researchers discover NG2+ cells may impact ALS disease progression

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

AACN endorses intraosseous vascular access

Health professionals invited for 1st Asia-Pacific Osteoporosis Meeting

Cardiac surgery leads to stroke, seizure and neurological complications: Report

Research on CBS protein may lead to new drug design for homocystinuria disorder

U-M researcher awarded $600,000 grant for study of progesterone in treatment of children with TBI

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Neurologic complications remain an important cause of morbidity and mortality after heart surgeries

Bayer presents results from Phase III ROCKET AF trial for atrial fibrillation at American Heart Association

Research suggests targeting spleen may promote healing of spinal cord injury

StemCells seeks Swiss authorization to conduct human neural stem cells clinical trial in chronic spinal cord injury

Event guide: The 7th CNS Drug Delivery Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News